Evidence-Based Approaches to Intensive Chemotherapy in Secondary AML

Author(s):

Margaret T. Kasner, MD,Christian Fidler, MD

Panelists discuss how the NCCN guidelines recommend intensive chemotherapy options, including traditional 7+3 and CPX-351, for newly diagnosed high-risk or secondary AML patients, with treatment selection based on individual patient factors and potential adverse effects.

EP: 1.Implementing Updates to AML Classification Guidelines

EP: 2.Treatment Goals in Secondary AML

EP: 3.The Role of Molecular and Cytogenetic Testing in Secondary AML

EP: 4.Patient-Centered Decision-Making in Secondary AML Treatment

EP: 5.Assessing Transplant Eligibility and Fitness for Intensive Chemotherapy

Now Viewing

EP: 6.Evidence-Based Approaches to Intensive Chemotherapy in Secondary AML

EP: 7.Navigating Intensive Chemotherapy in the Community Setting

EP: 8.Optimizing AML Care Through Academic-Community Collaboration

EP: 9.Practice Pearls for Treatment of Secondary AML in the Community Setting

Video content above is prompted by the following:

Please discuss the NCCN guideline recommended first-line treatment options for patients with newly diagnosed high-risk or secondary AML who are potential candidates for intensive chemotherapy induction.
Please briefly review the study design & efficacy study of CPX-351 vs. 7+3.
How do you monitor and manage potential adverse effects in these patients?
- Describe management of both 7+3 and CPX-351.
- How does your approach differ between the two regimens?